14.82
0.06 (0.41%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Crescent Biopharma, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| CBIO | - | - | - | 2.43 |
| SONN | 33 M | - | - | 2.07 |
| CELC | - | - | - | 83.17 |
| ALGS | - | - | - | 1.41 |
| MNPR | - | - | - | 3.66 |
| REPL | - | - | - | 10.78 |
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | 0.2 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 2.0 |
| 技术平均移动指标 参考 | -2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 新闻情绪 参考 | NA |
| 市场环境 | ×0.79 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.4% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | -1.7 |
| 最终评分 | 0.06 |
|
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.16% |
| 机构持股比例 | 22.26% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 03 Nov 2026 | Yahoo Finance |
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee… |
| 02 Nov 2026 | Yahoo Finance |
Crescent Biopharma to Present at November Investor Conferences
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at… |
| 15 Oct 2026 | Yahoo Finance |
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Comb
More than 125 patients dosed in ASCEND across the United States, Europe and South Korea; dose escalation complete On track to report initial monotherapy data from ASCEND in Q1 2027, including antitumor response for a first-line non-small cell lung cancer (NSCLC) cohort Enrolling patients in CR-001… |
| 05 Oct 2026 | Yahoo Finance |
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026 Initial clinical data expected in the second half of 2027… |
| 03 Sep 2026 | Yahoo Finance |
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda. |
| 03 Sep 2026 | Yahoo Finance |
Crescent Biopharma to Present at September Investor Conferences
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at… |
| 4年平均股息收益率 | 0.14% |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 13 Jan 2023 | 26 Dec 2022 | 12 Jan 2023 | 0.24 现金 |
| 21 Sep 2022 | 24 Aug 2022 | 20 Sep 2022 | 1.43 现金 |
| 20 Aug 2015 | 04 Aug 2015 | 19 Aug 2015 | 1.6492 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2023 | 0.240 | 1 | 0.10 |
| 2022 | 1.43 | 1 | 0.47 |
投资组合